## Contents

I. Disease and Treatment Information in Renal Cell Carcinoma ............................................................... 2

II. Recent News Articles in Renal Cell Carcinoma .................................................................................................. 2
   - Medscape Medical News (free password required) ....................................................................................... 2
   - MedpageToday .................................................................................................................................................. 3
   - Reuters Health .................................................................................................................................................. 3

III. Press Releases in Renal Cell Carcinoma ............................................................................................................ 4
   - Eurekalert.org .................................................................................................................................................. 4
   - Newswise.com ................................................................................................................................................ 9
   - Google.com .................................................................................................................................................... 13

IV. US Food and Drug Administration Info on Renal Cell Carcinoma ................................................................. 14
   - Drugs@FDA Database ..................................................................................................................................... 14
   - 2011 Advisory Committee Meetings ........................................................................................................ 17

V. Guidelines in Renal Cell Carcinoma .................................................................................................................... 17
   - National Guidelines Clearinghouse--Guidelines.gov ................................................................................... 17
   - National Comprehensive Cancer Network .................................................................................................. 20
   - American Urological Association ............................................................................................................ 20

VI. Conferences and Medical Associations for Renal Cell Carcinoma ................................................................... 21
   - Conferences .................................................................................................................................................. 21
   - Medical Associations .................................................................................................................................. 21

VII. Key Opinion Leaders in Renal Cell Carcinoma ................................................................................................. 21

VIII. Clinical Trials in Progress in Renal Cell Carcinoma ...................................................................................... 22

IX. PubMed Search in Renal Cell Carcinoma ........................................................................................................ 26
   - Randomized Controlled Trials .................................................................................................................. 26
   - Reviews ......................................................................................................................................................... 28
   - Editorials ....................................................................................................................................................... 37
I. Disease and Treatment Information in Renal Cell Carcinoma

- National Kidney Foundation- National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification [http://www.annals.org/content/139/2/137.full]

II. Recent News Articles in Renal Cell Carcinoma

Medscape Medical News (free password required)

[http://www.medscape.com/; search term = renal cell carcinoma; all results for the past 3 months.]

- Renal Cell Carcinoma in Kidney Graft Calls for Conservative Management De novo renal cell carcinoma (RCC) in a transplanted kidney should be managed conservatively, with graft preservation a primary goal, say researchers from ... News, Reuters Health Information, August 2011

- Nonaspirin NSAID Use Linked to Risk for Renal Cell Cancer Data from 2 prospective studies show an association between long-term use of nonaspirin anti-inflammatory drugs and the risk for renal cell cancer. News, Medscape Medical News, September 2011

- Surprise: Lenalidomide May Interact With P-Glycoprotein... myeloma. Temsirolimus, which has been approved for the treatment of renal cell carcinoma, is an ester prodrug of the macrocyclic immunosuppressive ... News, Medscape Medical News, August 2011

- ‘Strongest Ever Data' in Breast Cancer With Everolimus The combination of everolimus plus exemestane has produced the strongest data ever seen in estrogen-receptor (ER)-positive breast cancer. News, Medscape Medical News, September 2011
mTOR Inhibitors 'On the Right Track' for Tuberous Sclerosis... which does happen, such as when the growths in the kidney transform into renal cell carcinoma. The defects in the TSC1/2 genes responsible for TSC... News, Medscape Medical News, July 2011

Health Canada Approves Everolimus for Pediatric Brain Tumors... progressive neuroendocrine tumors of pancreatic origin, and advanced renal cell carcinoma refractory to sunitinib or sorafenib therapy. Everolimus, ... News, Medscape Medical News, September 2011

Meta-Analysis Defines Congestive Heart Failure Risk With Sunitinib The cancer drug sunitinib (Sutent; Pfizer) nearly doubles patients' relative risk of new-onset congestive heart failure (CHF) and triples their risk of... News, Reuters Health Information, August 2011

Hypertension Increases Risk for Cancer Death High blood pressure increased the risk of dying from cancer in men and women, and increased the incidence of cancer in men. News, Medscape Medical News, September 2011

MedpageToday
http://www.medpagetoday.com/; search term = renal cell carcinoma; all results for the past 3 months.

Medical News: NSAIDs, Not Aspirin, Linked With Renal Cancer
9/12/2011
Long-term use of certain analgesics has been linked with an increased risk of renal cell cancer, analysis of prospective data showed.

Reuters Health
www.reutershealth.com; search term = renal cell carcinoma; all results for the past 3 months.

Novartis drug Afinitor® helps women with advanced breast cancer...

... more than 70 countries and regions including the United States and the European Union in the oncology settings of advanced renal cell carcinoma (RCC) following...

Sun Sep 25, 2011 6:03pm EDT

UPDATE 1-Bristol-Myers gains more rights to cancer drug from Ono
... immunotherapy drug is in Phase I and Phase II development across a variety of tumor types and treatment settings, including renal cell carcinoma and melanoma. ...

Tue Sep 20, 2011 10:56pm EDT

Novartis receives EU approval for Votubia®, the first medication ...
... Afinitor is also approved in the EU for the treatment of patients with advanced renal cell carcinoma whose disease has progressed on or after treatment with ...

Thu Sep 8, 2011 1:15am EDT

Phase III trial of Novartis drug Afinitor® met primary endpoint ...
... Afinitor is approved in the EU for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with ...

Fri Jul 8, 2011 1:16am EDT

Novartis drug Afinitor® met primary endpoint of Phase III study ...
... everolimus Afinitor ® (everolimus) tablets is approved in the European Union (EU) for the treatment of patients with advanced renal cell carcinoma (RCC) whose ...

Tue Jul 5, 2011 1:16am EDT

III. Press Releases in Renal Cell Carcinoma

Eurekalert.org

www.eurekalert.org; search term = “renal cell carcinoma”; first 20 results.

Cancer-seeking 'smart bombs' target Renal Cell Carcinoma cells
... antibodies to home in on renal cell carcinoma ... in on antigens associated with renal cell carcinoma. Patients with progressive ... treatment options for patients with renal cell carcinoma," says Wim Oyen ...

Lymphocyte count indicates the prognosis of patients with renal cell carcinoma
... Lymphocyte count indicates the prognosis of patients with renal cell carcinoma Results suggest that ... simple and effective prognostic indicator in patients with
renal cell carcinoma (RCC). Sunil Saroha, MD ...

Renal Cell Carcinoma discovery could expand treatment options
Oregon Health & Science University Knight Cancer Institute researchers uncovered a gene that may be the key to helping Renal Cell Carcinoma patients who don't respond to current therapies. This discovery could also provide a ...

Researchers discover that lymphocyte count indicates prognosis of patients with renal cell ...
... that lymphocyte count indicates prognosis of patients with renal cell carcinoma Results suggest that ... simple and effective prognostic indicator in patients with renal cell carcinoma (RCC). Sunil Saroha, MD ...

Renal cancer drug temsirolimus shows promise against mesothelioma ...
... protein that regulates cell growth, which can slow tumor growth. It's used to treat advanced renal cell carcinoma. But researchers in Austria have found that temsirolimus also may slow ...

Renal Cell Carcinoma patients who have partial organ removal are healthier ...
... fields have been surprised that patient survival rates haven’t increased despite earlier diagnosis of renal cell carcinoma. That concern led to studies on partial vs. whole-organ removal. The ...
**Everolimus improves progression-free survival for patients with rare pancreatic cancer**

... in cancer cells. The once-daily oral therapy was approved in March 2009 for advanced renal cell carcinoma, and is currently being tested in a host of other disease sites ...


---

**Cancer drug used in combination with other therapies associated with increased risk of ...**

... types of advanced cancer, including colorectal cancer, non-small cell lung cancer, breast cancer, and renal cell carcinoma. "Even though a number of FAEs have been reported in patients treated ...


---

**Research provides new Renal Cell Carcinoma clues**

In a collaborative project involving scientists from three continents, researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer. The gene -- called PBRM1 -- ...


---

**Novel therapy for metastatic Renal Cell Carcinoma developed at VCU Massey Cancer Center**

... VCU Institute of Molecular Medicine (VIMM) have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the ...


---

**John Theurer Cancer Center to present innovative research at 2 surgical meetings**

... on a patient with a pathologic fracture of his right proximal humerus due to metastatic renal cell carcinoma. Medical imaging showed this fracture of the proximal humerus with a large ...

Public Press Releases

4th EAU NEEM in Riga opens tomorrow
... cancer, treatment options in upper tract TCC to the limitations of nephron-sparing surgery in renal cell carcinoma," said Dr. Alvis Laukmanis, president of the Latvian Urological Association and local ... http://www.eurekalert.org/pub_releases/2010-09/eaou-4en090910.php- 6.5KB - Public Press Releases

Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation
The unprecedented growth and promise of using thermal ablation to target and kill cancer is the subject of the Journal of Vascular and Interventional Radiology's August supplement, "Thermal Ablation 2010: At the ... http://www.eurekalert.org/pub_releases/2010-08/soir-jov082610.php- 9.8KB - Public Press Releases

Ablation proved as effective as traditional surgery in treating Renal Cell Carcinoma
... CT scan). Of the 208 patients who underwent the RFA procedure, 160 were diagnosed with renal cell carcinoma, a type of Renal Cell Carcinoma that is slow-growing but malignant and ... http://www.eurekalert.org/pub_releases/2010-06/usmc-apa060210.php- 8.4KB - Public Press Releases

Mayo Clinic study identifies surgical means for improving Renal Cell Carcinoma survival
... treatment of Renal Cell Carcinoma, specifically renal cell carcinoma, and how patients ... type of Renal Cell Carcinoma is renal cell carcinoma. The incidence of ... Mayo Clinic study of 888 renal cell carcinoma patients, those patients ... http://www.eurekalert.org/pub_releases/2010-06/mc-mcs060110.php- 10.4KB - Public Press Releases
New tool for pre-surgical detection of Renal Cell Carcinomas may help patients avoid unnecessary ...  
... imaging can help to distinguish clear-cell renal cell carcinoma (RCC), the predominant variant of ... lethal type of Renal Cell Carcinoma (clear cell renal cell carcinoma). When injected intravenously as part ...  

Researchers find papillary renal cell carcinoma unresponsive to sunitinib  
... Researchers find papillary renal cell carcinoma unresponsive to sunitinib ... 38,000 Americans diagnosed with renal cell carcinoma (RCC) each year ... really need to investigate papillary renal cell carcinoma separately from clear ...  

Mayo Clinic researchers find genetic secrets to common Renal Cell Carcinoma  
... common Renal Cell Carcinoma JACKSONVILLE, Fla. — By examining expression of every human gene in clear cell renal cell carcinoma (ccRCC) compared to normal kidney cells, researchers at Mayo Clinic’s campus ...  

Milk and risk of renal cell cancer: Genetic research sheds new light  
... suggested a connection between milk intake and renal cell carcinoma risk, and whether this represents ... study, the difference in the odds of renal cell carcinoma was approximately 35 percent. However ...  

EAU Congress plenary session: Advances in Renal Cell Carcinoma management  
Renal cell carcinoma accounts for about 3 percent of all solid tumors in adults, and worldwide, more than 200,000 new cases and 100,000 deaths result each year from this malignancy.  
http://www.eurekalert.org/pub_releases/2010-04/eaou-ecp041710.php - 9.3KB -
Newwise.com

www.newwise.com; search term = renal cell carcinoma, sorted by date. Results 1 through 20 of 95

Kidney Preserving Surgery Saves Bone Health

University of California, San Diego Health Sciences

2011-08-04

Researchers at the University of California, San Diego School of Medicine have shed new light on how surgery impacts both chronic kidney disease and bone health, particularly in women. For the first time, their findings point to the importance of pursuing kidney-sparing surgery in an effort to preserve kidney function and to reduce the risk of bone fractures later in life.

NewYork-Presbyterian/Columbia Research Presented at American Society of Clinical Oncologists Meeting

NewYork-Presbyterian Hospital/Columbia University Medical Center

2011-06-03

Among those presenting at this year's American Society of Clinical Oncologists meeting are physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center. The meeting takes place June 3–7, at McCormick Place, Chicago.

Christopher Kane, MD, Appointed Parsons Endowed Chair

University of California, San Diego Health Sciences

2011-05-26

Internationally-recognized cancer surgeon, Christopher Kane, MD, professor of surgery and chief, division of urology, has been named the inaugural holder of the C. Lowell and JoEllen Parsons Endowed Chair in Urology. The $2.5 million endowed faculty chair will enable Kane to recruit world-class talent and to support novel research and cancer treatment and prevention programs at UC San Diego Health System.

AACR Inaugurates New Leadership

American Association for Cancer Research (AACR)

2011-03-25
Judy E. Garber, M.D., M.P.H., was inaugurated today as president of the American Association for Cancer Research at the AACR 102nd Annual Meeting 2011. This year’s meeting theme is “Innovation and Collaboration: The Path to Progress.”

Research Advances Fight Against Renal Cell Carcinoma

UT Southwestern Medical Center

2011-03-30

Researchers at UT Southwestern Medical Center have discovered genetic pathways to starve selectively Renal Cell Carcinoma cells.

AACR Elects President-Elect, Directors and Nominating Committee Members

American Association for Cancer Research (AACR)

2011-03-25

The members of the American Association for Cancer Research have elected Frank McCormick, Ph.D., D.Sc. (hon.), as their president-elect. McCormick is the director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He holds the E. Dixon Heise distinguished professorship in oncology and the David A. Wood distinguished professorship of tumor biology and cancer research at UCSF. Additionally, he is the associate dean of the UCSF School of Medicine and a distinguished professor in residence in the department of microbiology and immunology as well as in the department of biochemistry and biophysics.

AACR Elects President-Elect, Directors and Nominating Committee Members

American Association for Cancer Research (AACR)

2011-03-22

The members of the American Association for Cancer Research have elected Frank McCormick, Ph.D., D.Sc. (hon.), as their president-elect. McCormick is the director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He holds the E. Dixon Heise distinguished professorship in oncology and the David A. Wood distinguished professorship of tumor biology and cancer research at UCSF. Additionally, he is the associate dean of the UCSF School of Medicine and a distinguished professor in residence in the department of microbiology and immunology as well as in the department of biochemistry and biophysics.

Everolimus Improves Progression-Free Survival for Patients with Rare Pancreatic Cancer

University of Texas M. D. Anderson Cancer Center

2011-02-09
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers from The University of Texas MD Anderson Cancer Center.

Novel Therapy for Metastatic Renal Cell Carcinoma Developed at VCU Massey Cancer Center

Virginia Commonwealth University

2010-12-14

Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the primary tumor site but also in distant tumors not directly infected by the virus.

Everolimus Improves Progression-Free Survival for Patients with Rare Pancreatic Cancer

University of Texas M. D. Anderson Cancer Center

2010-10-11

In an international Phase III randomized study, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET).

Belly Button Surgery for Renal Cell Carcinoma

University of California, San Diego Health Sciences

2010-07-29

Surgeons at the University of California, San Diego School of Medicine continue to advance minimally-invasive surgery for cancer patients by reducing the number of abdominal incisions from approximately six to a single small incision.

Widely Used Cancer Drug May Increase Risk for Proteinuria in Patients

Stony Brook University Medical Center

2010-06-10

Cancer patients treated with the chemotherapy agent bevacizumab (Avastin) may be at an increased risk of severe loss of protein from the kidney into the urine that can lead to significant kidney damage.
Ablation Proved as Effective as Traditional Surgery in Treating Renal Cell Carcinoma

UT Southwestern Medical Center
2010-06-02

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.

Study Identifies Surgical Means for Improving Renal Cell Carcinoma Survival

Mayo Clinic
2010-06-01

When Renal Cell Carcinoma spreads to other body parts, patients usually receive a poor prognosis. A new Mayo Clinic study examined the benefits of surgical treatment of Renal Cell Carcinoma, specifically renal cell carcinoma, and how patients saw improved prognosis of their cancer.

Researchers Find Gene They Believe Is Key to Renal Cell Carcinoma

Mayo Clinic
2010-05-20

Researchers at Mayo Clinic’s campus in Florida have discovered a key gene that, when turned off, promotes the development of common Renal Cell Carcinoma. Their findings suggest that a combination of agents now being tested in other cancers may turn the gene back on, providing a much-needed therapy for the difficult-to-treat cancer.

Researchers Find Genetic Secrets to Common Renal Cell Carcinoma

Mayo Clinic
2010-05-18

By examining expression of every human gene in clear cell renal cell carcinoma (ccRCC) compared to normal kidney cells, researchers at Mayo Clinic’s campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat Renal Cell Carcinoma.

Milk and Risk of Renal Cell Cancer: Genetic Research Sheds New Light

American Association for Cancer Research (AACR)
2010-05-03
While previous research had suggested that drinking milk was related to factors that may increase the risk of renal cell cancer, results of a recent study exploiting the genetic contribution to variation in milk consumption suggest that this may not be the case.

**Saving Kidneys with Large Tumors**

**University of California, San Diego Health Sciences**

2010-05-03

A multicenter team of investigators led by the University of California, San Diego School of Medicine has demonstrated, for the first time, the safety and efficacy of a targeted medication to shrink advanced Renal Cell Carcinomas prior to partial kidney removal and reconstruction.

**AACR and Landon Foundation Support the Next Generation of Researchers with the INNOVATOR Awards**

**American Association for Cancer Research (AACR)**

2010-04-13

The American Association for Cancer Research and the Kirk A. and Dorothy P. Landon Foundation will present three INNOVATOR Awards at the AACR 101st Annual Meeting 2010, held April 17-21, in Washington, D.C.

**Patient Trial of Personalized Two-Drug Therapy for Brain Tumors Launched**

**Cedars-Sinai Medical Center**

2010-04-08

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

**Google.com**

Search term = “renal cell carcinoma press releases”. All 3 results.

1. Add Url - Submit Site - Health & Well-Being > Pharmaceuticals ...

www.avivadirectory.com/Health/.../mTOR-Kinase-Inhibitors/Cached

You +1'd this publicly. Undo
The company site for Afinitor tablets outlines data about the product including its use for treatment of advanced renal cell carcinoma, press releases, ...

2. renal cell carcinoma News - FierceBiotech
www.fiercebiotech.com/tags/renal-cell-carcinomaCached

You +1’d this publicly. Undo

4 Jan 2007 – renal cell carcinoma Press Releases. Two Metabolon Studies Provide Insight into Renal Cell Carcinoma for University of California Davis ...

3. PRESS RELEASE Cancer Patient's Marathon Fundraiser for Charity
www.docstoc.com/.../PRESS-RELEASE-Cancer-Patients-Marathon- ...

You +1’d this publicly. Undo

7 Oct 2009 – ... online store, renal cell carcinoma, press releases, country music marathon, advertising agency, cancer patients, clinical trial search, ...

IV. US Food and Drug Administration Info on Renal Cell Carcinoma

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUR-WASH</td>
<td>PURIFIED WATER</td>
<td>S</td>
<td>S</td>
<td>NIAGARA</td>
<td>09/01/2011</td>
</tr>
</tbody>
</table>

Drugs@FDA Database

Original New Drug Approvals (NDAs and BLAs) by Month; last 3 months listed


October 2011

None

September 2011
### Renal Cell Carcinoma

**LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE**  
(NDA # 202171)

<table>
<thead>
<tr>
<th>Active Ingredients</th>
<th>Company</th>
<th>Generic Code</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE</td>
<td>MATRIX LABS LTD</td>
<td>4</td>
<td>09/08/2011</td>
</tr>
</tbody>
</table>

**LAMIVUDINE; ZIDOVUDINE**  
(NDA # 201151)

<table>
<thead>
<tr>
<th>Active Ingredients</th>
<th>Company</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAMIVUDINE; ZIDOVUDINE</td>
<td>CIPLA LIMITED</td>
<td>09/22/2011</td>
</tr>
</tbody>
</table>

**MEMANTINE HYDROCHLORIDE**  
(NDA # 200155)

<table>
<thead>
<tr>
<th>Active Ingredients</th>
<th>Company</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEMANTINE HYDROCHLORIDE</td>
<td>TORRENT PHARMS</td>
<td>09/27/2011</td>
</tr>
</tbody>
</table>

**CLOBETASOL PROPIONATE**  
(NDA # 201402)

<table>
<thead>
<tr>
<th>Active Ingredients</th>
<th>Company</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLOBETASOL PROPIONATE</td>
<td>PERRIGO ISRAEL</td>
<td>09/27/2011</td>
</tr>
</tbody>
</table>

### August 2011

**GEMCITABINE HYDROCHLORIDE**  
(NDA # 200795)

<table>
<thead>
<tr>
<th>Active Ingredients</th>
<th>Company</th>
<th>Generic Code</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEMCITABINE HYDROCHLORIDE</td>
<td>HOSPIRA INC</td>
<td>3</td>
<td>08/04/2011</td>
</tr>
</tbody>
</table>

**ROSUVASTATIN ZINC**  
(NDA # 202172)

<table>
<thead>
<tr>
<th>Active Ingredients</th>
<th>Company</th>
<th>Generic Code</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROSUVASTATIN ZINC</td>
<td>WATSON LABS INC</td>
<td>2</td>
<td>08/04/2011</td>
</tr>
</tbody>
</table>

**COMPLERA**  
(NDA # 202123)

<table>
<thead>
<tr>
<th>Active Ingredients</th>
<th>Company</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE</td>
<td>GILEAD SCIENCES INC</td>
<td>08/10/2011</td>
</tr>
</tbody>
</table>

**ZELBORAF**  
(NDA # 202429)

<table>
<thead>
<tr>
<th>Active Ingredients</th>
<th>Company</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEMURAFENIB</td>
<td>HOFFMAN LA ROCHE</td>
<td>08/17/2011</td>
</tr>
</tbody>
</table>
## July 2011

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCAPTA NEOHALER (NDA # 022383)</td>
<td>INDACATEROL MALEATE</td>
<td>1</td>
<td>S</td>
<td>NOVARTIS</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>XARELTO (NDA # 022406)</td>
<td>RIVAROXABAN</td>
<td>1</td>
<td>S</td>
<td>JOHNSON AND JOHNSON</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>BRILINTA (NDA # 022433)</td>
<td>TICAGRELOR</td>
<td>1</td>
<td>S</td>
<td>ASTRAZENECA LP</td>
<td>07/20/2011</td>
</tr>
<tr>
<td>HEPARIN SODIUM (NDA # 201370)</td>
<td>HEPARIN SODIUM</td>
<td>5</td>
<td>S</td>
<td>PFIZER</td>
<td>07/21/2011</td>
</tr>
<tr>
<td>HEPARIN SODIUM PRESERVATIVE FREE</td>
<td>HEPARIN SODIUM</td>
<td>5</td>
<td>S</td>
<td>PFIZER</td>
<td>07/21/2011</td>
</tr>
</tbody>
</table>
V. Guidelines in Renal Cell Carcinoma

National Guidelines Clearinghouse--Guidelines.gov

www.guidelines.gov; Search criteria = “renal cell carcinoma” all years, sorted by date, all 17 listed


   American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)


   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.].
<table>
<thead>
<tr>
<th></th>
<th><strong>Renal Cell Carcinoma</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>European Association of Urology - Medical Specialty Society.</em></td>
<td>View all guidelines by the developer(s)</td>
</tr>
<tr>
<td></td>
<td><em>American College of Radiology - Medical Specialty Society.</em></td>
<td>View all guidelines by the developer(s)</td>
</tr>
<tr>
<td></td>
<td><em>American College of Radiology - Medical Specialty Society.</em></td>
<td>View all guidelines by the developer(s)</td>
</tr>
<tr>
<td>6.</td>
<td><strong>Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma.</strong></td>
<td>2009 Aug. NGC:007628</td>
</tr>
<tr>
<td></td>
<td><em>National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.].</em></td>
<td>View all guidelines by the developer(s)</td>
</tr>
<tr>
<td></td>
<td><em>Program in Evidence-based Care - State/Local Government Agency [Non-U.S.].</em></td>
<td>View all guidelines by the developer(s)</td>
</tr>
<tr>
<td>8.</td>
<td><strong>Sunitinib for the first-line treatment of advanced and/or metastatic renal cell</strong></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Year (Revised)</td>
</tr>
<tr>
<td>-----</td>
<td>-----------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>10</td>
<td>Guideline for management of the clinical stage 1 renal mass.</td>
<td>2009</td>
</tr>
<tr>
<td>14</td>
<td>ACR Appropriateness Criteria® renal failure.</td>
<td>1995 (revised 2008)</td>
</tr>
</tbody>
</table>
15. **Renal cell carcinoma.** 2006 Oct. NGC:006065
   Association of Comprehensive Cancer Centres - Disease Specific Society. View all guidelines by the developer(s)

   European Federation of Neurological Societies - Medical Specialty Society. View all guidelines by the developer(s)

17. **Interleukin-2 in the treatment of patients with unresectable or metastatic renal cell cancer: a clinical practice guideline.** 2006 Jun 8. NGC:005223
   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)

---

**National Comprehensive Cancer Network**

Free password required

- [www.nccn.org](http://www.nccn.org)
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) in Renal Cell Carcinoma

**American Urological Association**

- [www.auanet.org](http://www.auanet.org)
- American Urological Association Guideline for Management of the Clinical Stage 1 Renal Mass
  - [http://www.auanet.org/content/media/renalmass09.pdf](http://www.auanet.org/content/media/renalmass09.pdf)
VI. Conferences and Medical Associations for Renal Cell Carcinoma

Conferences

- Renal Cell Carcinoma Association International Renal Cell Carcinoma Symposium
  http://www.kidneycancer.org/knowledge/learn/medical-education-programs
- Renal and Bladder Cancer National Conference http://www.mahealthcareevents.co.uk/cgi-bin/go.pl/conferences/detail.html?conference_uid=276
- European Association of Urology Annual Congress
  http://www.eauparis2012.org/scientific-programme/abstracts/

Medical Associations

- Kidney Cancer Association
- American Cancer Society (ACS)
- National Kidney Foundation
- American Association for Cancer Research (AACR)
- American Cancer Society (ACS)
- American Institute for Cancer Research (AICR)
- American Urological Association (AUA)

VII. Key Opinion Leaders in Renal Cell Carcinoma

A listing of key opinion leaders (KOLs) in Renal Cell Carcinoma who have participated in recent CME activities available online. Where possible, the sponsor information has been listed.

- Elizabeth R. Plimack, MD, MS, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. No relevant financial relationships disclosed.
- Gary R. Hudes, MD, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. No relevant financial relationships disclosed.
- Vladimir A. Valera, MD, Postdoctoral Visiting Fellow, Translational Surgical Pathology section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland. No relevant financial relationships disclosed.
- Maria J. Merino, MD, Chief, Translational Surgical Pathology section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland. No relevant financial relationships disclosed.
**VIII. Clinical Trials in Progress in Renal Cell Carcinoma**

Clinical trials.gov

**Search criteria - renal cell carcinoma | Open Studies | Exclude Unknown | Phase III, IV**

30 of 30 studies listed

<table>
<thead>
<tr>
<th>Rank</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.</td>
</tr>
<tr>
<td></td>
<td><strong>Condition:</strong> Renal Cell Carcinoma</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention:</strong> Other: Non-interventional</td>
</tr>
<tr>
<td>2</td>
<td>IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma</td>
</tr>
<tr>
<td></td>
<td><strong>Condition:</strong> Metastatic Renal Cell Carcinoma</td>
</tr>
</tbody>
</table>
Interventions: Drug: Sunitinib; Biological: IMA901 plus GM-CSF; Drug: Cyclophosphamide

3 Biological, Pathological and Imagery Markers in the First-Line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Sunitinib (SUTENT)

4 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

Conditions: Metastatic Renal Cell Carcinoma; Patients Who Have Progressed on or After the First VEGF-targeted Therapy
Intervention: Drug: Everolimus

5 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: sorafenib tosilate; Procedure: adjuvant therapy

6 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma That Progressed After First-Line Therapy

Condition: Renal Cell Carcinoma
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo

7 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery

8 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

Condition: Renal Cell Carcinoma
Intervention: Other: Endurance exercise

9 Study of TKI258 Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: TKI258; Drug: Sorafenib

10 Renal Cell Carcinoma (RCC) Scramble

Condition: Renal Cell Carcinoma
Intervention: Procedure: Perfusion CT scan

11 Sequential Study to Treat Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Sunitinib (Sutent); Drug: Sorafenib (Nexavar)

12 Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent

Condition: Renal Cell Carcinoma
Intervention: Other: Non Interventional

13 Everolimus in Treating Patients With Renal Cell Carcinoma Who Have Undergone Surgery

Condition: Renal Cell Carcinoma
Interventions: Drug: everolimus; Other: placebo

14 Study to Observe Safety and Efficacy of Nexavar in Treatment of Renal Cell Carcinoma

Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)

15 A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo

16 Clinical Trial to Assess the Importance of Nephrectomy

Condition: Metastatic Renal Cell Carcinoma
Interventions: Procedure: Nephrectomy; Other: Sunitinib alone

17 Caphosol in Oral Mucositis Due to Targeted Therapy

Conditions: Oral Mucositis; Renal Cell Carcinoma; Hepatocellular Carcinoma; Gastrointestinal Stromal Tumors
Interventions: Other: supersaturated calcium-phosphate rinse; Other: sodium chloride 0.9 %

18 Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib

19 Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
Conditions: Metastatic Renal Cell Carcinoma; Gastrointestinal Stromal Tumors
Intervention: Drug: Sunitinib malate

20 Cytochrome p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Conditions: Non Small-cell Lung Cancer; Renal-cell Cancer; Gastrointestinal Stroma Tumor
Interventions: Drug: Sunitinib; Drug: Erlotinib; Drug: Midazolam; Drug: Caffeine

21 Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Condition: Renal Cell Carcinoma
Intervention: Drug: Temsirolimus

22 Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For The Treatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo

23 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
Conditions: Renal Cell Carcinoma; Gastrointestinal Stromal Tumor
Interventions: Drug: usage oral angiogenesis inhibitor; Drug: stop oral angiogenesis inhibitor

24 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Conditions: Brain and Central Nervous System Tumors; Renal Cell Carcinoma; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate

25 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Conditions: Renal Cell Carcinoma; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery

26 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Condition: Renal Cell Carcinoma
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy

27 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Renal Cell Carcinoma; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy

28 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients Receiving Vincristine for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma

Conditions: Renal Cell Carcinoma; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma
Interventions: Dietary Supplement: glutamic acid; Other: placebo

29 Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma
Interventions: Device: SIR-Spheres; Drug: Sorafenib tosylate

30 Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Bevacizumab; Drug: Cyclophosphamide; Drug: methotrexate; Behavioral: Diet Intervention; Behavioral: Exercise Intervention

IX. PubMed Search in Renal Cell Carcinoma

Search = renal cell carcinoma, published in the last 180 days, English only

Randomized Controlled Trials

Results: 4

1.

Hitt Medical Writing, LLC © 2011 www.hittmedicalwriting.com
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.


PMID:

21664867

[PubMed - indexed for MEDLINE]

Related citations

2.

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.


PMID:

21448165

[PubMed - indexed for MEDLINE]

Related citations

3.

MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.


PMID:

21387109

[PubMed - indexed for MEDLINE]

Related citations

Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, Koshy B, Spraggs CF, Mooser VE, Cardon LR, Pandite LN.


PMID: 21145803

[PubMed - indexed for MEDLINE]

Related citations

Reviews

Results: 27

1. Wunderlich syndrome: cross-sectional imaging review.

Katabathina VS, Katre R, Prasad SR, Surabhi VR, Shanbhogue AK, Sunnapwar A.


PMID: 21765296

[PubMed - indexed for MEDLINE]

Related citations

2. Clinical genomics of renal epithelial tumors.

Hagenkord JM, Gatalica Z, Jonasch E, Monzon FA.

Renal Cell Carcinoma HittPack™

PMID:

21763625

[PubMed - indexed for MEDLINE]

Related citations

3.

Renal cell carcinoma: molecularly targeted therapy.
Cáceres W, Cruz-Chacón A.


PMID:

21682150

[PubMed - indexed for MEDLINE]

Related citations

4.

Renal cell carcinoma: treatment options.
Deveson Kell S.


PMID:

21647012

[PubMed - indexed for MEDLINE]

Related citations

5.

MicroRNAs as regulators of signal transduction in urological tumors.
Fendler A, Stephan C, Yousef GM, Jung K.

Metastatic renal cell carcinoma presenting as foot metastasis: case report and review of the literature.
Choufani E, Diligent J, Galois L, Mainard D.

Small renal mass: what the urologist needs to know for treatment planning and assessment of treatment results.
Stakhovskyi O, Yap SA, Leveridge M, Lawrentchuk N, Jewett MA.

Renal cell carcinoma: what the surgeon and treating physician need to know.
Chapin BF, Delacroix SE Jr, Wood CG.
Renal Cell Carcinoma HittPack™

PMID:

21606286

[PubMed - indexed for MEDLINE]

Related citations

9.

Diagnosis and management of urothelial carcinoma of the bladder.
Tanaka MF, Sonpavde G.

PMID:

21566415

[PubMed - indexed for MEDLINE]

Related citations

10.

Developments in kidney tumor nephrometry.
Lieser G, Simmons MN.

PMID:

21566414

[PubMed - indexed for MEDLINE]

Related citations

11.

Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.


PMID:
21490127
[PubMed - indexed for MEDLINE]
Related citations

16. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.
Padhy BM, Shanmugam SP, Gupta YK, Goyal A.
PMID:
21480952
[PubMed - indexed for MEDLINE]
Related citations

17. Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.
Berz D, Wanebo H.


PMID: 21480252

[PubMed - indexed for MEDLINE]

Related citations


PMID: 21459420

[PubMed - indexed for MEDLINE]

Related citations

Tykodi SS, Sandmaier BM, Warren EH, Thompson JA.

PMID: 21417772

[PubMed - indexed for MEDLINE]

Related citations

Ravaud A, Bello CL.


PMID:
21394020

[PubMed - indexed for MEDLINE]

Related citations

21.

von Hippel-Lindau disease: a clinical and scientific review.

Maher ER, Neumann HP, Richard S.


PMID:
21386872

[PubMed - indexed for MEDLINE]

Related citations

22.

Update on targeted therapies for clear cell renal cell carcinoma.

Singer EA, Gupta GN, Srinivasan R.


PMID:
21330923

[PubMed - indexed for MEDLINE]

Related citations

23.

Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.
Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised?

Long CJ, Kutikov A, Canter DJ, Egleston BL, Chen DY, Viterbo R, Boorjian SA, Uzzo RG.


PMID: 21062399

[PubMed - indexed for MEDLINE]


PMID: 20878529

[PubMed - indexed for MEDLINE]

Sunitinib for the treatment of metastatic renal cell carcinoma.
Oudard S, Beuselinck B, Decoene J, Albers P.
Cancer Treat Rev. 2011 May;37(3):178-84. Review.
PMID: 20817406
[PubMed - indexed for MEDLINE]
Related citations

Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma.
Tan KV, Namdarian B, Costello AJ, Hovens CM.
PMID: 19914100
[PubMed - indexed for MEDLINE]
Related citations

Editorials

Results: 22

1. Combination of targeted agents in metastatic renal cell carcinoma: A Path Forward or a Dead-End Street?
Michaelson MD.
PMID: 21898374
[PubMed - as supplied by publisher]
Related citations

2.


Sun M, Abdollah F, Bianchi M, Karakiewicz PI.


PMID:

21889837

[PubMed - as supplied by publisher]

Related citations

3.

Competing-Risks Analysis for Renal Cell Carcinoma: How Do We Accurately Communicate the Risks and Benefits of Treatment to Patients?

Kim SP, Thompson RH.


PMID:

21868148

[PubMed - as supplied by publisher]

Related citations

4.

Editorial Comment from Dr Maeda to Decompressive surgery in combination with preoperative transcatheter arterial embolization: Successful improvement of ambulatory function in renal cell carcinoma patients with metastatic extradural spinal cord compression.

Maeda Y.

PMID:
21815943
[PubMed - in process]

Related citations

5.
Editorial Comment from Dr Chang to Decompressive surgery in combination with preoperative transcatheter arterial embolization: Successful improvement of ambulatory function in renal cell carcinoma patients with metastatic extradural spinal cord compression.

Chang UK.


PMID:
21815942
[PubMed - in process]

Related citations

6.
Renal cell carcinoma: a changing paradigm with a need for consensus.

Mulders P, Kirkali Z.


PMID:
21778017
[PubMed - in process]

Related citations

7.
Renal cell carcinoma.
Choueiri TK.
PMID:
21763960
[PubMed - in process]

Related citations
8.

Editorial comment.
Huang WC.
PMID:
21712114
[PubMed - indexed for MEDLINE]

Related citations
9.

Safety Issues and Rationale for Neoadjuvant Approaches in Renal Cell Carcinoma.
Bessede T, Pignot G, Patard JJ.
PMID:
21684073
[PubMed - as supplied by publisher]

Related citations
10.
Sunitinib prior to planned cytoreductive nephrectomy: is this the new litmus test for metastatic renal cell carcinoma?

Kim SP, Thompson RH.


PMID:
21680083

[PubMed - in process]

Related citations

11. Editorial comment.

Best SL, Cadeddu JA.


PMID:
21624602

[PubMed - indexed for MEDLINE]

Related citations

12. Editorial comment.

Campbell SC.


PMID:
21624601

[PubMed - indexed for MEDLINE]

Related citations


PMID: 21599759

[PubMed - indexed for MEDLINE]

Related citations


White NM, Yousef GM.


PMID: 21571339

[PubMed - indexed for MEDLINE]

Related citations

15. Editorial comment.

Pomara G, Francesca F.


PMID: 21539964

[PubMed - indexed for MEDLINE]

Related citations
16. Targeted caval cytoreduction: solid foundations or shifting sands?

Bex A, Clarke N.


PMID:
21444147

[PubMed - indexed for MEDLINE]

Related citations

17. Does preoperative nutritional status affect survival in renal cell carcinoma? The debate continues.

Capitanio U, Montorsi F.


PMID:
21444146

[PubMed - indexed for MEDLINE]

Related citations

18. The future of nephron sparing procedures for renal masses: balancing costs, efficacy, patient outcomes and experience.

Lotan Y.


PMID:
21419436

[PubMed - indexed for MEDLINE]

Related citations
Ribal MJ.
PMID: 21296486
[PubMed - indexed for MEDLINE]
Related citations

20. Progression-free survival as a surrogate marker of overall survival: Is it the good question?
Escudier B.
PMID: 21287543
[PubMed - indexed for MEDLINE]
Related citations

21. Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
Escudier B.
PMID: 21278217
[PubMed - indexed for MEDLINE]
Related citations
22. 
*Lord of the rings: a promising novel treatment for renal cell carcinoma?*

Johansson M. 


**PMID:**

21276657

[PubMed - indexed for MEDLINE]

*Related citations*